Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Receivables - Other (2017 - 2025)

Integra Lifesciences Holdings' Receivables - Other history spans 9 years, with the latest figure at $6.8 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 11.36% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $6.8 million, up 11.36%, while the annual FY2025 figure was $6.8 million, 11.36% up from the prior year.
  • Receivables - Other for Q4 2025 was $6.8 million at Integra Lifesciences Holdings, up from $4.9 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $12.2 million in Q1 2022 and bottomed at $3.5 million in Q2 2025.
  • The 5-year median for Receivables - Other is $7.9 million (2021), against an average of $8.1 million.
  • The largest annual shift saw Receivables - Other skyrocketed 87.98% in 2022 before it tumbled 47.29% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $11.4 million in 2021, then dropped by 11.3% to $10.1 million in 2022, then decreased by 8.78% to $9.2 million in 2023, then tumbled by 33.43% to $6.1 million in 2024, then increased by 11.36% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Receivables - Other are $6.8 million (Q4 2025), $4.9 million (Q3 2025), and $3.5 million (Q2 2025).